Prevention of hepatitis B virus reactivation under rituximab therapy

Immunotherapy

Volumn 1, Issue 6, 2009, Pages 1053-1061

  Tsutsumi, Yutaka ^a   Yamamoto, Yoshiya ^a   Tanaka, Junji ^b   Asaka, Masahiro ^b   Imamura, Masahiro ^b   Masauzi, Nobuo ^a  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Hepatitis B virus; Lamivudine; Non Hodgkin's lymphoma; Reactivation; Rituximab

Indexed keywords

ADEFOVIR; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ENTECAVIR; EPIRUBICIN; FLUDARABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; PIRARUBICIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TELBIVUDINE; TENOFOVIR; VINCRISTINE; VIRUS DNA;

ADD ON THERAPY; BURKITT LYMPHOMA; CHEMOTHERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; MEDICAL RESEARCH; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION; VIRUS REACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARTHRITIS, RHEUMATOID; HEPATITIS; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSION; LAMIVUDINE; LYMPHOMA, NON-HODGKIN; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 77953443012     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.59     Document Type: Review

References (106)

1. Maloney DG, Liles TM, Czerwinski DK et al.: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457-2466 (1994).
2. Maloney DG, Grillo-Lopez AJ, White CA et al.: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188-2195 (1997).
3. Maloney DG, Grillo-Lopez AJ, Bodkin D et al.: IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15, 3266-3274 (1997).
4. Maclaughlin P, Grillo-Lopez AJ, Link BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1998).
5. Tobinai K, Kobayasi Y, Narabayashi M et al.; Members of the IDCE-C2B8 Study Group: Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in a relapsed B-cell lymphoma. Ann. Oncol. 9, 527-534 (1998).
6. Igarashi T, Ohtsu T, Fujii H et al.; Members of the IDEC-C2B8 Study Group: Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int. J. Hematol. 73, 213-221 (2001).
7. Coiffer B, Haioun N, Engert KA et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood 92, 1927-1932 (1998).
8. Foran JM, Rohatiner AZS, Cunningham D et al.: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytome, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. 18, 317-324 (2000).
9. Davis TA, White CA, Grillo-Lopez AJ et al.: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J. Clin. Oncol. 17, 1851-1857 (1999).
10. Ghielmini M, Hsh Schmitz SF, Burki K et al.: The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann. Oncol. 11, S123-S126 (2000).
11. Kunkel L, Wong A, Maneatis T et al.: Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphomas benefit-risk update. Semin. Oncol 27, 53-61 (2000). (Pubitemid 32166264)
12. Tobinai K: Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int. J. Hematol. 76, 411-419 (2002).
13. Igarashi T, Kobayashi Y, Ogura M et al.: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese Phase II study. Ann. Oncol. 13, 928-943 (2002).
14. Tobinai K, Igarashi T, Kobayashi Y et al: Japanese multicenter Phase II and pharmacokinetic study o rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann. Oncol. 15, 821-830 (2004).
15. Rothe A, Schulz H, Elter T, Engert A, Reiser M: Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica 89, 875-876 (2004). (Pubitemid 38981355)
16. Seymour JF: New treatment approaches to indolent non-Hodgkin's lymphoma. Semin. Oncol. 31, 27-32 (2004).
17. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 22, 4711-4716 (2004).
18. Coiffer B, Lepage E, Briere J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
19. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A: Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85, 894-895 (2000).
20. Sharma VR, Fleming DR, Slone S: Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96, 1184-1186 (2000).
21. Suzan F, Ammor M, Ribrag V: Fatal reactivation of cytomegalovirus infection after use of rituximab for a post transplantation lymphoproliferative disorder. N. Engl. J. Med. 345, 1000 (2001).
22. Goldberg SL, Pecora AL, Alter RS et al.: Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99, 1486-1488 (2002).
23. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ, Bagshawe KD: Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2, 538-1530 (1975).
24. Hoonfnagle JH, Dusheiko GM, Schafer DF et al.: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Intern. Med. 96, 447-449 (1982).
25. Thung SN, Gerber MA, Klion F, Gilbert H: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier. Arch. Intern. Med. 145, 1313-1314 (1985).
26. Lau JY, Lai CL, Lin HJ et al.: Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Quart. J. Med. 73, 911-917 (1989).
27. Bird GL, Smith H, Portmann B, Alexander GJ, Williams R: Acute liver decompensation of withdrawal of cytotoxic and immunosuppressive therapy in hepatitis B carriers. Quart. J. Med. 73, 895-902 (1989).
28. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd O, Chiu EKW: Hepatitis B infection in patients with lymphomas. Hematol. Oncol. 8, 261-270 (1990).
29. Lok ASF, Lai CL, Wu PC: Hepatitis B virus infection in Chinese families in Hong Kong. Am. J. Epidemiol. 126, 492-499 (1987).
30. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Tood D: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 100, 182-188 (1991).
31. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S: Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65, 878-884 (1990). (Pubitemid 20063489)
32. Soh LT, Ang PT, Sng I, Chua EJ, Ong YW: Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy. Eur. J. Cancer 28A, 1338-1339 (1992).
33. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E: Sever hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: survey in Japan, 1987-1991. Cancer 78, 2210-2215 (1996).
34. Kumagai K, Takagi T, Nakamura S et al.: Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann. Oncol. 8, 107-109 (1997).
35. Yeo W, Chan PKS, Zhong S et al.: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. J. Med. Virol. 62, 299-307 (2000).
36. Tsutsumi Y, Kanamori H, Mori A et al.: Reativation of hepatitis B virus with rituximab. Expert Opin. Drug Saf. 4, 599-608 (2005).
37. Tsutsumi Y, Shigematsu A, Hashino S et al.: Analysis of reactivation of hepatitis B virus in the treatment of B-cell non-Hodgkin's lymphoma in Hokkaido. Ann. Haematol. 88, 375-377 (2009). ■ Demonstrates the importance of clinical course anti-hepatitis B antibodies when hepatitis B virus (HBV) reactivates.
38. Czuczman MS, Grillo-Lopez AJ, White CA et al.: Treatment of patients with low grade B-cell lymphoma with the combination of chemeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17, 268-276 (1999).
39. Hernandez JA, Diloy R, Salat D, del Rio N, Martinez X, Castellvi JM: Fluminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 88(6), ECR22 (2003).
40. Skrabs C, Muller C, Agis H, Mannhalter C, Jager U: Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 16, 1884-1886 (2002).
41. Westhoff TH, Jochimsen F, Schmittel A et al.: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102, 1930 (2003).
42. Ng HJ, Lim LC: Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann. Hematol. 80, 549-552 (2001).
43. Jager G, Neumeister P, Brezinschek R et al.: Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a Phase II study. Eur. J. Haematol. 69, 21-26 (2002).
44. Dervite I, Hober D, Morel P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med. 344, 68-69 (2001).
45. Rossini F, Capalbo S, Fumagalli M et al.: 'Standard dose' rituximab in refractory chronic lymphocytic leukemia. Hematol. J. 3 (Suppl. 1), 0827 (2002).
46. Domingo-Domenech E, Gonzalez-Barca E, Estany C, Sureda A, Besalduch J, de Sevilla AF: Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica 87, 1229-1230 (2002). (Pubitemid 35397786)
47. Tsutsumi Y, Kawamura T, Saitoh S et al.: Hepatitis B virus reactivation in a case of Non-Hodgkin's lymphoma treated with chemotherapy and rituximab (necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy). Leuk. Lymphoma 45, 627-629 (2004). (Pubitemid 38196051)
48. Tsutsumi Y, Tanaka J, Kawamura T et al.: Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann. Haematol. 83, 58-60 (2004).
49. Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL: Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lympohma. Eur. J. Med. Res. 13, 483-486 (2008).
50. Sera T, Hiasa Y, Michitaka K et al.: Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern. Med. 45(11), 721-724 (2006).
51. Uemura T, Kiyosawa K: Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern. Med. 45(12), 747-748 (2006).
52. Yang SH, Kuo SH: Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann. Haematol. 87, 325-327 (2008).
53. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV: Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825-829 (1999). (Pubitemid 29291352)
54. Webster GJ, Reignat S, Maini MK et al.: Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanism. Hepatology 32, 1117-1124 (2000). (Pubitemid 30808439)
55. Foy E, Li K, Wang C et al.: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145-1148 (2003). (Pubitemid 36583099)
56. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM.: Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107-110 (1999).
57. Gale M Jr, Blakely CM, Kwieciszewski B et al.: Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanism of kinase regulation. Mol. Cell. Biol. 18, 5208-5218 (1998).
58. Lok AS, Heathcote EJ, Hoofnagel JH: Management of hepatitis B 2000 - summary of a workshop. Gastroenterology 120, 1828-1853 (2001).
59. Vento S, Cainelli F, Longhi MS: Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. 3, 333-340 (2002). (Pubitemid 34661982)
60. Chen AL: Steroid free chemotherapy decrease the risk of hepatitis flare ups in hepatitis B virus carriers with nonHodgkin's lymphoma. Blood 87, 1627-1631 (1996).
61. Yeo W, Chan TC, Leung NW et al.: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 27, 605-611 (2009). ■ Analyzes the risk factors of HBV reactivation under the chemotherapy.
62. Yeo W, Zee B, Zhong S et al.: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoin cytotoxic chemotherapy. Br. J Cancer 90, 1306-1311 (2004). (Pubitemid 38586252)
63. Loombs R, Rowley A, Wesley R et al.: Systemic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 148, 519-528 (2008).
64. Coiffier B: Hapatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of lamivudine prophylaxis. Cancer Invest. 24, 548-552 (2006).
65. Lau GK, Yiu HH, Fong DY et al.: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125, 1742-1749 (2003).
66. Al-Taie OH, Mork H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M: Prevention of hepatitis B flare-up during chemotherapy using lamivdine: case report and review of the literature. Ann. Hematol. 78, 247-249 (1999).
67. Silvestri F, Ermacora A, Sperotto A et al.: Lamivdine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br. J. Haematol. 108, 394-396 (2000).
68. Shiboiet O, Gillis S, Hubert A, Shouval D, Safadi R: Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100, 391-396 (2002). (Pubitemid 34761098)
69. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM: Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53, 1363-1365 (2004). (Pubitemid 39120128)
70. Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G: Frequency of hepatitis B virus mutant in asymptomatic hepatitis virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol. J. 5, 325-328 (2004). (Pubitemid 39214210)
71. Cil T, Altintas A, Pasa S, Bayan K, Ozekinci T, Isikdogan A: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBsAg) seroporsitive cancer patients undergoing cytotoxic chemotherapy. Leuk. Lymphoma 49, 939-947 (2008). (Pubitemid 351942748)
72. Simpson ND, Simpson PW, Ahmed AM et al.: Prophylaxis agent chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J. Clin. Gastroenterol. 37, 68-71 (2003).
73. Dai, MS, Wu PF,Shyu RY, Lu JJ, Chao TY: Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 24, 540-546 (2004).
74. Idilman R: Lamivudine prophylaxis in HBV crriers with haemato-oncological malignancies who receive chemotherapy. J. Antimicrob. Chemother. 55, 828-831 (2005).
75. Jang JW, Choi JY, Base SH et al.: A randomized controlled study of preemptive lamivudine in patients receiving transterial chemo-lipiodolization. Hepatology 43, 233-240 (2006).
76. Li YH, He YF, Jiang WQ et al.: Lamivudine prophylaxis reduce the incidence and severty of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106, 1320-1325 (2006).
77. Yeo W, Ho WM, Hui P et al.: Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 88, 209-215 (2004).
78. Mimidis K, Tsatalas C, Margaritis D et al.: Efficacy of lamivdine in patients with hamatologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematol. 107, 49-51 (2002). (Pubitemid 34701966)
79. Hamaki T, Kami M, Kusumi E et al.: Prophylaxis of hapatitis B reactivation using amivdine in a patient receiving rituximab. Am. J. Hematol. 68, 292-294 (2001).
80. Kami M, Hamaki T, Murashige N et al.: Safty of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol. J. 4, 159-162 (2003).
81. He YF, Li YH, Wang FH et al.: The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann. Hematol. 87, 481-485 (2008).
82. Lok ASF, McMahon BJ: Chronic hepatitis B: update of recommendations. Hepatology 39, 857-861 (2004).
83. Lok ASF, McMahon BJ: Chronic hepatitis B. Hepatology 34, 1225-1241 (2001).
84. Picardi M, Pane F, Quintarelli C et al.: Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 88, 1296-1303 (2003). (Pubitemid 37456385)
85. Miyagawa M, Minami M, Fujii K et al.: Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy. J. Med. Virol. 80, 2069-2078 (2008).
86. Lok AS, Mcmahon BJ: Chronic hepatitis B. Hepatology 45, 507-539 (2007). ■ Guidelines for the management of chronic hepatitis B from the American Association for the Study of Liver Diseases.
87. Hui CK, Cheung WWW, Zhang HY et al.: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131, 59-68 (2006). ■ Demonstrates the HBV reactivation in hepatitis B surface antigen-negative patients.
88. Liaw YF, Leung N, Guan R et al.: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 25, 472-489 (2005). ? Guidelines for the management of chronic hepatitis B from the Asia Pacific Association for the Study of the Liver.
89. European Association for the Study of the Liver EASL clinical practice guidelines: Management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009). ■ Guidelines for the management of chronic hepatitis B from the European Association for the Study of the Liver.
90. Hu KQ: Occult hepatitis B virus infection and its clinical implications. J. Viral Hepatitis 9, 243-257 (2002).
91. Yeo W, Lam C, Zee B et al.: Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol. 15, 1661-1666 (2004).
92. Awerkiew S, Daumer M, Reiser M et al.: Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lympohma patient. J. Clin. Virol. 38, 83-86 (2007).
93. Onozawa M, Hashino S, Izumiyama K et al.: Progressive disappearance of anti-hepatitis surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79, 616-619 (2005). ■ Demonstrates the HBV reactivation systems after hematopoietic stem cell transplantation.
94. Allain JP: Occult hepatitis B virus infection. Transfus. Clin. Biol. 11, 18-25 (2004).
95. Liang R: How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113(14), 3147-3153 (2009).
96. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM: Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann. Hematol. 83, 769-774 (2004).
97. Gracia-Rodrigues MJ, Canales MA, Hernandez-Maraver D, Hernadez-Navarro F: Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment. Am. J Hematol. 83, 673-675 (2008).
98. Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P: Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B cell lymphoma. Br. J. Dermatol. 155, 1053-1056 (2006).
99. Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser TA: Reactivation of hepatitis B two yers after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution. Clin. Transphnt. 431-434 (2009).
100. Yeo W, Johnson PJ: Diagnosis, preventon and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43, 209-220 (2006). (Pubitemid 43303989)
101. Papatheodoridis GV, Manolakapoulos S, Dusheiko G, Archimandritis A: Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect. Dis. 8, 167-178 (2008).
102. Fung SK, Andereone P, Han SH et al.: Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 43, 937-943 (2005).
103. Peters MG, Hann HW, Martin P et al.: Adeforvir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126, 91-101 (2004). (Pubitemid 38040727)
104. Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC: Adeforvir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N. Engl. J. Med. 352, 310-311 (2004).
105. Tillmann HL, Wedemeyer H, Manns MP: Treatment of hepatitis B in special patient groups: hemodialysis heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. J. Hepatol. 39, S206-S211 (2003). (Pubitemid 37222674)
106. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos P et al.: Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8(3), R83 (2006).